Evidence map›Paper›PMID 42279306›Full record

ArticleCancers2026

Prognostic Significance of Inflammatory Biomarkers in First-Line Immunotherapy for Metastatic Melanoma: Multicentric Study.

Branko Dujovic, Aleksandar Popovic, Amina Jalovcic Suljevic, Bojana Cikota-Aleksic, Mirjana Balic, Igor Salatic, Jovana Pavlica, Philipp Schnecko, Tanja Mesti, Muamer Terzo and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Branko DujovicClinic for Dermatovenerology, Military Medical Academy, University of Defense, 11000 Belgrade, Serbia.ORCID 0009-0009-1497-5777
Aleksandar PopovicClinic for Oncology, Clinical Centre of Niš, 18000 Niš, Serbia.ORCID 0000-0001-7114-0068
Amina Jalovcic SuljevicClinic of Oncology, Clinical Center University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina.
Bojana Cikota-AleksicCentre for Clinical Pharmacology, Military Medical Academy, 11000 Belgrade, Serbia.
Mirjana BalicClinic for Oncology, Clinical Centre of Niš, 18000 Niš, Serbia.
Igor SalaticClinic for Dermatovenerology, Military Medical Academy, University of Defense, 11000 Belgrade, Serbia.ORCID 0009-0008-0297-2168
Jovana PavlicaClinic for Dermatovenerology, Military Medical Academy, University of Defense, 11000 Belgrade, Serbia.ORCID 0009-0006-8307-8218
Philipp SchneckoAlcedis, a HUMA Company, 35394 Giessen, Germany.
Tanja MestiInstitute of Oncology, 1000 Ljubljana, Slovenia.ORCID 0000-0002-6129-532X
Muamer TerzoClinic of Oncology, Clinical Center University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina.ORCID 0009-0004-5874-451X
Emina Bicakcic FilipovicClinic of Oncology, Clinical Center University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina.ORCID 0000-0002-4891-1749
Lidija KandolfClinic for Dermatovenerology, Military Medical Academy, University of Defense, 11000 Belgrade, Serbia.ORCID 0000-0002-5221-5068

Funding

Science Fund of the Republic of Serbia 6795
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

first-line immunotherapyimmune checkpoint inhibitorsinflammatory biomarkersmetastatic melanomaoverall survivalprognostic factorsprogression-free survival

Identifiers

PMID42279306
PMCPMC13255854

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.